BioWorld Asia

Dec. 14, 2005

BioAlliance Pharma Completes Initial Public Offering For EUR30M

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International) Read More

Domantis' Valuation Higher For £17M Third Financing

Dutch Team Finds Aspects Of Cell Cycle Checkpoints

Zealand Pharma Learning Lessons From Pulled IPO

Group Of GMO Crop Raiders Acquitted By French Court

Cellartis Brings In EUR 8M For Embryonic Stem Cell Work

Alizyme Reports Positive Data For Cetilistat, Plans Phase III

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...